240 related articles for article (PubMed ID: 19125021)
1. The immunogenicity of tumor cell death.
Kepp O; Tesniere A; Zitvogel L; Kroemer G
Curr Opin Oncol; 2009 Jan; 21(1):71-6. PubMed ID: 19125021
[TBL] [Abstract][Full Text] [Related]
2. Immunogenic cell death modalities and their impact on cancer treatment.
Kepp O; Tesniere A; Schlemmer F; Michaud M; Senovilla L; Zitvogel L; Kroemer G
Apoptosis; 2009 Apr; 14(4):364-75. PubMed ID: 19145485
[TBL] [Abstract][Full Text] [Related]
3. Molecular characteristics of immunogenic cancer cell death.
Tesniere A; Panaretakis T; Kepp O; Apetoh L; Ghiringhelli F; Zitvogel L; Kroemer G
Cell Death Differ; 2008 Jan; 15(1):3-12. PubMed ID: 18007663
[TBL] [Abstract][Full Text] [Related]
4. Immunogenic cancer cell death: a key-lock paradigm.
Tesniere A; Apetoh L; Ghiringhelli F; Joza N; Panaretakis T; Kepp O; Schlemmer F; Zitvogel L; Kroemer G
Curr Opin Immunol; 2008 Oct; 20(5):504-11. PubMed ID: 18573340
[TBL] [Abstract][Full Text] [Related]
5. Ecto-calreticulin in immunogenic chemotherapy.
Obeid M; Tesniere A; Panaretakis T; Tufi R; Joza N; van Endert P; Ghiringhelli F; Apetoh L; Chaput N; Flament C; Ullrich E; de Botton S; Zitvogel L; Kroemer G
Immunol Rev; 2007 Dec; 220():22-34. PubMed ID: 17979837
[TBL] [Abstract][Full Text] [Related]
6. Human tumor cells killed by anthracyclines induce a tumor-specific immune response.
Fucikova J; Kralikova P; Fialova A; Brtnicky T; Rob L; Bartunkova J; Spísek R
Cancer Res; 2011 Jul; 71(14):4821-33. PubMed ID: 21602432
[TBL] [Abstract][Full Text] [Related]
7. Immunogenic death of colon cancer cells treated with oxaliplatin.
Tesniere A; Schlemmer F; Boige V; Kepp O; Martins I; Ghiringhelli F; Aymeric L; Michaud M; Apetoh L; Barault L; Mendiboure J; Pignon JP; Jooste V; van Endert P; Ducreux M; Zitvogel L; Piard F; Kroemer G
Oncogene; 2010 Jan; 29(4):482-91. PubMed ID: 19881547
[TBL] [Abstract][Full Text] [Related]
8. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity.
Aymeric L; Apetoh L; Ghiringhelli F; Tesniere A; Martins I; Kroemer G; Smyth MJ; Zitvogel L
Cancer Res; 2010 Feb; 70(3):855-8. PubMed ID: 20086177
[TBL] [Abstract][Full Text] [Related]
9. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy.
Apetoh L; Ghiringhelli F; Tesniere A; Criollo A; Ortiz C; Lidereau R; Mariette C; Chaput N; Mira JP; Delaloge S; André F; Tursz T; Kroemer G; Zitvogel L
Immunol Rev; 2007 Dec; 220():47-59. PubMed ID: 17979839
[TBL] [Abstract][Full Text] [Related]
10. Witch hunt against tumor cells enhanced by dendritic cells.
Locher C; Rusakiewicz S; Tesnière A; Ghiringhelli F; Apetoh L; Kroemer G; Zitvogel L
Ann N Y Acad Sci; 2009 Sep; 1174():51-60. PubMed ID: 19769736
[TBL] [Abstract][Full Text] [Related]
11. Tumor stress, cell death and the ensuing immune response.
Ullrich E; Bonmort M; Mignot G; Kroemer G; Zitvogel L
Cell Death Differ; 2008 Jan; 15(1):21-8. PubMed ID: 17992190
[TBL] [Abstract][Full Text] [Related]
12. High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy.
Dong Xda E; Ito N; Lotze MT; Demarco RA; Popovic P; Shand SH; Watkins S; Winikoff S; Brown CK; Bartlett DL; Zeh HJ
J Immunother; 2007 Sep; 30(6):596-606. PubMed ID: 17667523
[TBL] [Abstract][Full Text] [Related]
13. [Immunological aspects of anticancer chemotherapy].
Zitvogel L; Tesniere A; Apetoh L; Ghiringhelli F; Kroemer G
Bull Acad Natl Med; 2008 Oct; 192(7):1469-87; discussion 1487-9. PubMed ID: 19445369
[TBL] [Abstract][Full Text] [Related]
14. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy.
Kepp O; Galluzzi L; Martins I; Schlemmer F; Adjemian S; Michaud M; Sukkurwala AQ; Menger L; Zitvogel L; Kroemer G
Cancer Metastasis Rev; 2011 Mar; 30(1):61-9. PubMed ID: 21249425
[TBL] [Abstract][Full Text] [Related]
15. Post-apoptotic tumors are more palatable to dendritic cells and enhance their antigen cross-presentation activity.
Brusa D; Garetto S; Chiorino G; Scatolini M; Migliore E; Camussi G; Matera L
Vaccine; 2008 Nov; 26(50):6422-32. PubMed ID: 18848858
[TBL] [Abstract][Full Text] [Related]
16. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies.
Apetoh L; Tesniere A; Ghiringhelli F; Kroemer G; Zitvogel L
Cancer Res; 2008 Jun; 68(11):4026-30. PubMed ID: 18519658
[TBL] [Abstract][Full Text] [Related]
17. Reduction of endoplasmic reticulum Ca2+ levels favors plasma membrane surface exposure of calreticulin.
Tufi R; Panaretakis T; Bianchi K; Criollo A; Fazi B; Di Sano F; Tesniere A; Kepp O; Paterlini-Brechot P; Zitvogel L; Piacentini M; Szabadkai G; Kroemer G
Cell Death Differ; 2008 Feb; 15(2):274-82. PubMed ID: 18034188
[TBL] [Abstract][Full Text] [Related]
18. HMGB1: a two-headed signal regulating tumor progression and immunity.
Campana L; Bosurgi L; Rovere-Querini P
Curr Opin Immunol; 2008 Oct; 20(5):518-23. PubMed ID: 18599281
[TBL] [Abstract][Full Text] [Related]
19. Decoding dangerous death: how cytotoxic chemotherapy invokes inflammation, immunity or nothing at all.
van der Most RG; Currie AJ; Robinson BW; Lake RA
Cell Death Differ; 2008 Jan; 15(1):13-20. PubMed ID: 18007666
[TBL] [Abstract][Full Text] [Related]
20. Immunogenic anti-cancer chemotherapy as an emerging concept.
Haynes NM; van der Most RG; Lake RA; Smyth MJ
Curr Opin Immunol; 2008 Oct; 20(5):545-57. PubMed ID: 18573339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]